| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1378674 | Bioorganic & Medicinal Chemistry Letters | 2006 | 6 Pages |
Abstract
A novel class of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-ones have been discovered and developed as potent and selective GlyT1 inhibitors. The molecules display excellent selectivities (when compared to their triazaspiropiperidine analogues) against the μ opioid receptor as well as the nociceptin/orphanin FQ peptide (NOP) receptor.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Daniela Alberati, Simona M. Ceccarelli, Synèse Jolidon, Eva A. Krafft, Anke Kurt, Axel Maier, Emmanuel Pinard, Henri Stalder, Deborah Studer, Andrew W. Thomas, Daniel Zimmerli,
![First Page Preview: Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: Achieving selectivity against the μ opioid and nociceptin/orphanin FQ peptide (NOP) receptors Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: Achieving selectivity against the μ opioid and nociceptin/orphanin FQ peptide (NOP) receptors](/preview/png/1378674.png)